Bicycle Therapeutics plc

NASDAQ:BCYC

Biotechnology

Healthcare
$3.20 -1.36%

-$0.06 today

Market cap
$224.30M
Beta
1.54
P/E (TTM)
-1.3
EPS (TTM)
-$3.14
52W Low $3.95High $9.18

Volume 0.45M

Average 0.49M

Fair Value & DCF

Compare our fair value with your own assumptions

Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.

Bicycle Therapeutics plc

NASDAQ:BCYC

Intrinsic Alpha fair value

Locked

Current Price

$3.20

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Build your own valuation

Test an independent scenario and compare it with Intrinsic Alpha's estimate.

Sign in to use the DCF calculator

Free accounts get 5 valuations per week. Upgrade for more.

Sign in / Sign up

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A4 analysts
RevenueN/AN/A+71.2%
+12.4% (5yr)4 analysts
Net IncomeN/AN/AN/A
N/A4 analysts
EBITN/AN/AN/A
N/A4 analysts

Analysis

Recent growth has been strongest in Revenue at +71.2% over three years. Forward estimates point to Revenue at +12.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Estimates & History

Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.

Further estimates hidden. Sign in to unlock

Competitor Valuations

Peer stocks ranked by intrinsic value status

CompanyMarket CapPriceValuationP/E1Y Return

KalVista Pharmaceuticals, Inc.

NASDAQ:KALV

$1.44B$27.00Not rated-9.9+89.21%

Omeros Corporation

NASDAQ:OMER

$1.27B$17.49Not rated8.4+63.76%

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

$796.97M$1.79Not rated-30.5+21.09%

4D Molecular Therapeutics, Inc.

NASDAQ:FDMT

$675.64M$12.23Not rated-4.0+6.94%

Prothena Corporation plc

NASDAQ:PRTA

$419.01M$8.16Not rated-3.1-20.27%

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

$287.64M$3.77Not rated-3.6-61.46%

ADC Therapeutics S.A.

NYSE:ADCT

$171.07M$1.34Not rated-1.2-66.25%

Compass Therapeutics, Inc.

NASDAQ:CMPX

$139.35M$0.77Not rated-5.5-87.69%

Neumora Therapeutics, Inc. Common Stock

NASDAQ:NMRA

$80.59M$0.43Not rated-1.2-87.42%